share_log

Avalo Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer VARKI PAUL

Avalo Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer VARKI PAUL

Avalo Therapeutics | 3:首次持股声明-高管 VARKI PAUL
美股sec公告 ·  06/25 16:06
Moomoo AI 已提取核心信息
Paul Varki, the Chief Legal Officer of Avalo Therapeutics, Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3 requirements. The document, dated 06/24/2024, indicates that Varki does not beneficially own any non-derivative or derivative securities of the company. The filing was completed on 06/25/2024 and was submitted as an individual filing. This formality is part of the regulatory compliance under Section 16(a) of the Securities Exchange Act of 1934, which mandates reporting by directors, officers, or owners of more than ten percent of a class of the company's equity securities.
Paul Varki, the Chief Legal Officer of Avalo Therapeutics, Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3 requirements. The document, dated 06/24/2024, indicates that Varki does not beneficially own any non-derivative or derivative securities of the company. The filing was completed on 06/25/2024 and was submitted as an individual filing. This formality is part of the regulatory compliance under Section 16(a) of the Securities Exchange Act of 1934, which mandates reporting by directors, officers, or owners of more than ten percent of a class of the company's equity securities.
Avalo Therapeutics, Inc.的首席法律官Paul Varki根据Form 3的要求向SEC提交了关于有益所有权的初始声明。文件日期为06/24/2024,表明Varki没有拥有公司的任何非衍生或衍生证券。申报于06/25/2024完成,并作为个人申报提交。这种形式属于《证券交易法》第16(a)条规定的监管合规性,该条规定了公司董事、高管或持有公司某一类权益证券超过10%的所有者报告的要求。
Avalo Therapeutics, Inc.的首席法律官Paul Varki根据Form 3的要求向SEC提交了关于有益所有权的初始声明。文件日期为06/24/2024,表明Varki没有拥有公司的任何非衍生或衍生证券。申报于06/25/2024完成,并作为个人申报提交。这种形式属于《证券交易法》第16(a)条规定的监管合规性,该条规定了公司董事、高管或持有公司某一类权益证券超过10%的所有者报告的要求。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息